pemetrexed viatris 25 mg/ml inf. sol. (conc.) i.v. vial
viatris gx bv-srl - pemetrexed diarginine - eq. pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed diarginine - pemetrexed
pemetrexed teva 100 mg inj. sol. (pwdr., conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed disodium - eq. pemetrexed 100 mg - powder for concentrate for solution for infusion - 100 mg - pemetrexed disodium - pemetrexed
pemetrexed teva 500 mg inj. sol. (pwdr., conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed disodium - eq. pemetrexed 500 mg - powder for concentrate for solution for infusion - 500 mg - pemetrexed disodium - pemetrexed
pemetrexed teva 1000 mg inj. sol. (pwdr., conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed disodium - eq. pemetrexed 1000 mg - powder for concentrate for solution for infusion - 1000 mg - pemetrexed disodium - pemetrexed
pemetrexed teva 25 mg/ml inf. sol. (conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed 25 mg/ml - pemetrexed
pemetrexed teva 25 mg/ml inf. sol. (conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed 25 mg/ml - pemetrexed
pemetrexed teva 25 mg/ml inf. sol. (conc.) i.v. vial
teva pharma belgium sa-nv - pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed 25 mg/ml - pemetrexed
pemetrexed teva rtu 25 mgml
abic marketing ltd, israel - pemetrexed - concentrate for solution for infusion - pemetrexed 25 mg / 1 ml - pemetrexed - pemetrexed teva rtu in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed teva rtu in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva rtu is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva rtu is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
pemetrexed teva rtu 25 mgml
abic marketing ltd, israel - pemetrexed - concentrate for solution for infusion - pemetrexed 25 mg / 1 ml - pemetrexed - pemetrexed teva rtu in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed teva rtu in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva rtu is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva rtu is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
pemetrexed waverley 100 mg inj. sol. (pwdr., conc.) i.v. vial
waverley pharma europe ltd. - pemetrexed disodium - eq. pemetrexed 100 mg - powder for concentrate for solution for infusion - 100 mg - pemetrexed disodium - pemetrexed